Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-05-31 08:00 | English | 1.4 MB | |||
| 2023-05-31 08:00 |
Change of number of shares and votes in Xbrane
|
English | 66.0 KB | ||
| 2023-05-31 08:00 |
Förändrat antal aktier och röster i Xbrane
|
Swedish | 66.3 KB | ||
| 2023-05-26 08:00 |
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany
|
English | 82.7 KB | ||
| 2023-05-26 08:00 |
STADA och Xbrane lanserar Ximluci® som ranibizumab biosimilar i Tyskland
|
Swedish | 75.4 KB | ||
| 2023-05-23 01:05 |
Xbrane has carried out a directed share issue and an issue of convertible bonds…
|
English | 90.4 KB | ||
| 2023-05-23 01:05 |
Xbrane har genomfört en riktad nyemission samt en emission av konvertibla oblig…
|
Swedish | 90.9 KB | ||
| 2023-05-22 17:31 |
Xbrane announces its intention to carry out a directed share issue and an issue…
|
English | 88.6 KB | ||
| 2023-05-22 17:31 |
Xbrane offentliggör avsikt att genomföra en riktad nyemission och en emission a…
|
Swedish | 88.6 KB | ||
| 2023-05-04 18:32 |
Announcement from Xbrane Biopharma's annual general meeting
|
English | 65.0 KB | ||
| 2023-05-04 18:32 |
Kommuniké från årsstämman i Xbrane Biopharma
|
Swedish | 64.0 KB | ||
| 2023-04-25 07:00 |
STADA och Xbrane levererar Ximluci® (ranibizumab) i England under kontrakt med …
|
Swedish | 85.1 KB | ||
| 2023-04-25 07:00 |
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract
|
English | 85.9 KB | ||
| 2023-04-24 07:00 |
XBRANE submits BLA for ranibizumab biosimilar candidate to FDA
|
English | 68.4 KB | ||
| 2023-04-24 07:00 |
XBRANE skickar in ansökan om marknadsgodkännande för sin ranibizumab biosimilar…
|
Swedish | 69.6 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
